Closing the Loop on Pain: Real-Time ECAP Feedback in Spinal Cord Stimulation
By Nicholas A. Russo, D.O., Anesthesiologist, Interventional Pain Medicine Physician, The University of Chicago Pritzker School of Medicine
A 52-year-old nurse who used to run along Lake Erie before undergoing two back surgeries and escalating opioid use was left anchored to her recliner. Even with high-dose medications, her pain hovered around 8 out of 10, until she received a closed-loop spinal cord stimulator (SCS). Unlike traditional systems, this one monitors her spinal cord’s own electrical signals, evoked compound action potentials, or ECAPs, and adjusts the stimulation in real time. Within weeks, her pain dropped below a 2, and she was back to walking the lakefront.
Stories like this reflect a larger shift in how we approach neuromodulation. Traditional “open loop” SCS systems deliver fixed electrical parameters without accounting for physiological shifts that happen with posture, breathing, or cerebrospinal fluid dynamics. As a result, the therapy often under- or over-stimulates. Closed-loop SCS, guided by ECAPs, brings a new level of responsiveness, adjusting stimulation on the fly to keep patients consistently within a therapeutic range.
ECAP-controlled therapy doesn’t just offer more relief; it offers steadier, smarter relief that moves with the patient.
We’ve come a long way since spinal cord stimulation was first introduced in 1967. Open loop systems can be effective, but they often lose ground over time. Roughly 13% of initially successful implants lose efficacy each year, in large part because static settings can’t keep up with even small movements of the spinal cord within the dura. That’s where ECAPs come in.
An ECAP is essentially a snapshot of how many A-beta fibers are activated by a stimulus pulse; its amplitude increases with the number of fibers recruited. Measuring ECAPs allows the system to quantify the “dose” of neural activation, pulse by pulse. With that information, it can automatically fine-tune each subsequent pulse to maintain a consistent effect. It’s a bit like a pacemaker, but instead of keeping the heart in rhythm, it’s keeping pain signals in check.
Closed-loop SCS represents more than just a technical upgrade; it’s an electroceutical. We’re no longer limited to subjective impressions of pain relief. ECAPs give us a physiological biomarker we can actually use to dose, similar to medications. In a specialty like pain medicine, where so much is subjective, this kind of objective feedback is rare and valuable. It holds promise for a future where pain treatment is not only more effective, but also measurable and personalized.
Technologically, these systems include an implantable pulse generator, multi-contact leads, a differential amplifier to record ECAPs, and a digital controller. The clinician sets a target ECAP amplitude, typically between 40-60 µV, and the device dynamically adjusts the current with each pulse, often up to 10,000 times per minute. In lab testing, ECAPs stayed within ±4 µV of the target over 24 hours.
Clinical data backs this up. The Avalon feasibility study showed that 85.7% of patients achieved at least 50% relief of back pain, and nearly two-thirds had over 80% relief at six
months. In an extended follow-up, 81% maintained that benefit at 12 months, spending most of their day within the programmed ECAP range.
The Evoke randomized controlled trial, the largest and most rigorous to date, demonstrated the superiority of closed-loop over open-loop SCS at every time point:
– 12 months: 83% vs. 61% meeting ≥50% pain relief (p = 0.006)
– 24 months: 79% vs. 54%
– 36 months: 78% vs. 49%, with nearly half of closed-loop patients achieving ≥80% relief
Additionally, patients reported decreased opioid use, improved function, and better sleep. In the crossover ECHO-MAC study, 88% preferred closed-loop overall, citing fewer overstimulation events and a more stable therapy experience.
What’s more, closed-loop systems maintained ECAPs above the therapeutic threshold over 98% of the time, with no loss of effect or increase in battery burden, even three years out. A comprehensive outcomes analysis also showed that patients were twice as likely to achieve global clinical benefit, including improvements in mood, function, and quality of life.
Economically, closed-loop SCS may also prove to be a smarter investment. A 2024 UK cost-utility model found it “dominates” open-loop SCS and conservative therapy in terms of quality-adjusted life years (QALYs) and long-term cost, thanks largely to improved durability and fewer explants.
Of course, there are limitations. Implanting ECAP-sensing leads requires precise electrode positioning, which may involve a learning curve for some providers. Real-time adjustment uses slightly more power, about 10–15% more, but recharge times remain manageable. Some payers still consider closed-loop “investigational,” delaying access outside major centers. Patients with severe spinal stenosis or dense epidural scarring may have weak or inconsistent ECAP signals.
Still, the technology is moving forward. Second-generation systems are already incorporating machine learning to anticipate physiological changes before they occur, and new waveform designs are being explored to enhance comfort and effectiveness. Research is also expanding into areas like cervical myelopathy and visceral pain.
After five decades of trial-and-error programming, spinal cord stimulation finally has a feedback loop. ECAP-controlled therapy doesn’t just offer more relief; it offers steadier, smarter relief that moves with the patient. As data continues to grow and insurance coverage improves, closed-loop SCS could become the new standard for the millions still living with chronic pain.
References
1. Mekhail N, Levy RM, Deer TR, et al. Durability of Clinical and Quality-of-Life Outcomes of Closed-Loop Spinal Cord Stimulation for Chronic Back and Leg Pain. Pain Practice. 2022;22(2):145–154. doi:10.1111/papr.13050
2. Mekhail N, Levy RM, Deer TR, et al. Long-term safety and efficacy of closed loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double blind, randomised, controlled trial. The Lancet Neurology. 2022;21(3):271–280. doi:10.1016/S1474-4422(21)00443-1
3. Deer T, Mekhail N, Gill JS, et al. Effective Relief of Pain and Associated Symptoms With Closed-Loop Spinal Cord Stimulation System: Preliminary Results of the Avalon Study. Neuromodulation. 2021;24(4):732–740. doi:10.1111/ner.13328
4. Gill JS, Kramer J, Hunter CW, et al. Improvements in Therapy Experience With ECAP-Controlled, Closed-Loop Spinal Cord Stimulation – Primary Outcome of the ECHO-MAC Randomized Clinical Trial. Neuromodulation. 2022;25(2):235– 244. doi:10.1016/j.neurom.2021.09.002
5. North JM, Eldabe S, Burger K, et al. ECAP-controlled closed-loop versus open loop SCS for the treatment of chronic pain: 36-month results of the EVOKE blinded randomized clinical trial. Pain Practice. 2024. doi:10.1111/papr.13442
6. Falowski S, Levy R, Mekhail N, et al. Neurophysiological outcomes that sustained clinically significant improvements over 3 years of physiologic ECAP controlled closed-loop spinal cord stimulation for the treatment of chronic pain. Pain Practice. 2023;23(5):546–554. doi:10.1111/papr.13348
7. Wilson D, North JM, Eldabe S, et al. Durable multimodal and holistic response for physiologic closed-loop spinal cord stimulation supported by objective evidence from the EVOKE double-blind randomized controlled trial. Neuromodulation. 2023;26(1):105–113. doi:10.1016/j.neurom.2022.09.004
8. Duenas H, Falowski S, Poree L, et al. Early outcomes with a flexible ECAP based closed loop using multiplexed spinal cord stimulation waveforms – single-arm study with in-clinic randomized crossover testing. Neuromodulation. 2024. doi:10.1016/j.neurom.2024.03.001
9. Eldabe S, Veizi E, Thomson S, et al. Sustained Long-Term Outcomes With Closed-Loop Spinal Cord Stimulation: 12-Month Results of the Prospective, Multicenter, Open-Label Avalon Study. Neuromodulation. 2022;25(6):853–860. doi:10.1016/j.neurom.2022.03.010
10. Duarte RV, Thomson S, Eldabe S, et al. Network Meta-analysis and Economic Evaluation of Neurostimulation Interventions for Chronic Nonsurgical Refractory Back Pain. Neuromodulation. 2024. doi:10.1016/j.neurom.2024.01.012